US4749703A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Calcium antagonist piperazine derivatives, and compositions therefor
Assignee: Sumitomo Pharma Co Ltd
•
Filing: 1985-08-09
•
Granted: 1988-06-07
•
Expires: 2005-08-09
Abstract
Abstract PCT No. PCT/JP85/00445 Sec. 371 Date Apr. 10, 1986 Sec. 102(e) Date Apr. 10, 1986 PCT Filed Aug. 9, 1985 PCT Pub. No. WO86/01203 PCT Pub. Date Feb. 27, 1986.Compounds of the formula: <IMAGE> wherein A means an alkylene; Y-Z means <IMAGE> -CH=CH-, -CH2CH2-, or <IMAGE> R1 and R2 are each a substituent; R3 is hydrogen atom, alkyl, or alkoxy; R4 is phenyl, phenylalkyl, phenylalkenyl, diphenylmethyl, naphthyl, thiazolyl, optionally substituted pyridyl, optionally substituted pyrimidinyl, quinolyl, benzoylalkyl, benzoyl, furoyl, thenoyl, phenyloxycarbonyl, phenyloxysulfonyl, or phenylsulfonyl; a is 2 or 3, b and c are each 1 or 2, and d is an integer of 0 to 2, provided that the phenyl, phenyl moiety and naphthyl may optionally be substituted, and a pharmaceutically acceptable salt thereof, process for the preparation thereof, and pharmaceutical composition containing the same. The compounds and salt thereof show potent calcium antagonistic activity and are useful for prophylaxis and treatment of hypertension and/or ischemic heart disease.
Inventors
- 👤 Hitoshi Uno
- 👤 Mikio Kurokawa
- 👤 Fuminori Sato
- 👤 Naonobu Hatano
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 18:45
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/04; C07D295/14; C07D215/00; C07D215/02; C07D215/16; C07D215/38; A; A61; A61P; A61P3/00; A61P9/00; A61P9/10; A61P9/12; C07D213/00; C07D213/02; C07D213/04; C07D213/60; C07D213/72; C07D213/74; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/32; C07D239/42; C07D277/00; C07D277/02; C07D277/20; C07D277/32; C07D277/38; C07D295/145; C07D295/15; C07D337/00; C07D337/02; C07D337/06; C07D337/10; C07D337/12; C07D409/00; C07D409/02; C07D409/12
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
80 words
A compound of the formula: ##STR102## wherein n is 2, 3 or 4; Y--Z is ##STR103## --CH═CH-- or --CH 2 CH 2 --, d is 0, 1 or 2; R 1 is hydrogen, halogen, C 1-3 alkyl or C 1-3 alkoxy, and R 4 is phenyl, phenyl-C 1-3 alkyl, phenyl-C 3-5 alkenyl or pyridyl, wherein the phenyl and phenyl moiety in R 4 above definition is either unsubstituted or substituted by halogen or trifluoromethyl, or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
80 words
A compound of the formula: ##STR102## wherein n is 2, 3 or 4; Y--Z is ##STR103## --CH═CH-- or --CH 2 CH 2 --, d is 0, 1 or 2; R 1 is hydrogen, halogen, C 1-3 alkyl or C 1-3 alkoxy, and R 4 is phenyl, phenyl-C 1-3 alkyl, phenyl-C 3-5 alkenyl or pyridyl, wherein the phenyl and phenyl moiety in R 4 above definition is either unsubstituted or substituted by halogen or trifluoromethyl, or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
38 words
The compound according to claim 1, wherein n is 3; R 1 is hydrogen, fluorine, methyl or methoxy; R 4 is phenyl, phenyl substituted by halogen or trifluoromethyl, benzyl, cinnamyl or pyridyl, or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
42 words
The compound according to claim 1, wherein n is 3; Y--Z is ##STR104## R 1 is hydrogen, fluorine, methyl or methoxy; R 4 is phenyl, or 2 or 4-fluorophenyl, 2 or 4-chlorophenyl, cinnamyl, 3-trifluoromethylphenyl or 2-pyridyl, or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
31 words
The compound according to claim 1, wherein n is 3; Y--Z is --CH═CH--; R 1 is hydrogen or fluorine, R 4 is 4-fluorophenyl or cinnamyl, or a pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
15 words
The compound according to claim 1, which is 11-[4-[4-(4-fluorophenyl)-1-piperazinyl]butyrylamino]-6,11-dihydrodibenzo[b,e]thiepin, or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
15 words
The compound according to claim 1, which is 11-[4-[4-(4-fluorophenyl)-1-piperazinyl]butyrylamino]-2-methyl-6,11-dihydrodibenzo[b,e]thiepin, or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
15 words
The compound according to claim 1, which is 11-[4-[4-(4-fluorophenyl)-1-piperazinyl]butyrylamino]-6,11-dihydrodibenzo[b,e]thiepin-5-oxide, or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim
15 words
The compound according to claim 1, which is 11-[4-[4-(4-fluorophenyl)-1-piperazinyl]-butyrylamino]-6,11-dihydrodibenzo[b,e]thiepin-5,5-dioxide, or a pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim
15 words
The compound according to claim 1, which is 5-[4-[4-(4-fluorophenyl)-1-piperazinyl]butyrylamino]-5H-dibenzo[a,d]cycloheptene, or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
15 words
The compound according to claim 1, which is 3-fluoro-11-[4-[4-(4-fluorophenyl]-1-piperazinyl]butyrylamino]-6,11-dihydrodibenzo[b,e]thiepin or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim
37 words
A pharmaceutical composition having a calcium antagonistic activity, which comprises as an active ingredient an effective amount of a compound as set forth in claim 1, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Claim 13
Dependent Claim
26 words
The pharmaceutical composition according to claim 11, wherein the active ingredient is a compound as set forth in claim 2, or a pharmaceutically acceptable salt thereof.
Claim 14
Dependent Claim
26 words
The pharmaceutical composition according to claim 11, wherein the active ingredient is a compound as set forth in claim 3, or a pharmaceutically acceptable salt thereof.
Claim 15
Dependent Claim
26 words
The pharmaceutical composition according to claim 11, wherein the active ingredient is a compound as set forth in claim 4, or a pharmaceutically acceptable salt thereof.
Claim 16
Dependent Claim
26 words
The pharmaceutical composition according to claim 11, wherein the active ingredient is a compound as set forth in claim 5, or a pharmaceutically acceptable salt thereof.
Claim 17
Dependent Claim
26 words
The pharmaceutical composition according to claim 11, wherein the active ingredient is a compound as set forth in claim 6, or a pharmaceutically acceptable salt thereof.
Claim 18
Dependent Claim
26 words
The pharmaceutical composition according to claim 11, wherein the active ingredient is a compound as set forth in claim 7, or a pharmaceutically acceptable salt thereof.
Claim 19
Dependent Claim
26 words
The pharmaceutical composition according to claim 11, wherein the active ingredient is a compound as set forth in claim 8, or a pharmaceutically acceptable salt thereof.
Claim 20
Dependent Claim
26 words
The pharmaceutical composition according to claim 11, wherein the active ingredient is a compound as set forth in claim 9, or a pharmaceutically acceptable salt thereof.
Claim 21
Dependent Claim
26 words
The pharmaceutical composition according to claim 11, wherein the active ingredient is a compound as set forth in claim 10, or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
GB210533A
Cited
GB1284516A
Cited
US3849410A
Cited
JPS52111583A
Cited
US4278796A
Cited
JPS553353A
Cited
CS210369B1
Cited
JPS5874666A
Cited
JPS5896075A
Cited
US4457931A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-06-07 | 1991-12-07 | 1992-06-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-06-07 | 1995-12-07 | 1996-06-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-06-07 | 1999-12-07 | 2000-06-07 | $7700.00 | Window Closed / Lapsed |